eubiologics

Á¦Ç° ¹× ¿¬±¸°³¹ß

Development and supply of safe and effective vaccine for global public health

¸é¿ªÁõ°­Á¦

EcML¢â

EcML¢âÀº MLA(monophosphoryl lipid A)·Î ÇüÁúÀüȯµÈ ´ëÀå±ÕÀÇ ¼¼Æ÷¸·¿¡ MLA°¡ Á÷Á¢ ÃàÀûµÇµµ·Ï ÇÏ¿© »ê, ¿°±â °¡¼öºÐÇسª ÇÕ¼º°ú °°Àº º¹ÀâÇÑ Á¦Á¶°øÁ¤À» °ÅÄ¡Áö ¾Ê°í Á¦Á¶ÇÑ °í¼öÀ², °íÇ°ÁúÀÇ Á¦Ç° ÀÔ´Ï´Ù. EcML¢âÀº ¹é½ÅÀÇ ¸é¿ªÁõ°­Á¦(adjuvant)·Î »ç¿ëµÇ¸ç, TLR 4 agonist·Î ÀÛ¿ëÇÏ¿© ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀ» À¯µµÇÏ¿© ¸é¿ªÁõ°­ÀÇ È¿´ÉÀ» ³ªÅ¸³À´Ï´Ù.
ÀǾàÇ°¿ë ¸é¿ªÁõ°­Á¦´Â ÇöÀç±îÁö ¹é½ÅÀÇ ¸é¿ª¿ø¼ºÀ» ÁõÁø½ÃÅ°±â À§ÇÑ Adjuvant·Î¼­ ÀÎü ¹é½Å°³¹ß¿¡ ÁÖ·Î ÀÌ¿ëµÇ¾î ¿ÔÀ¸³ª ÃÖ±Ù ¸é¿ªÁõ°­Á¦ÀÇ ±¸Ã¼ÀûÀÎ ÀÛ¿ë±âÀüÀÌ ¹àÇôÁö°í ¸ö¼Ó ¸é¿ªÃ¼°è¸¦ Á¶ÀýÇØ ÁúȯÀ» ±Øº¹Çϱâ À§ÇÑ ¸é¿ªÄ¡·á¹ýÀÌ °¢±¤¹ÞÀ¸¸é¼­ Ç×¾Ï, ÀÚ°¡¸é¿ª Ä¡·á µîÀÇ ºÐ¾ß·Î Àû¿ë¹üÀ§¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ´ç»ç´Â EcML¢âÀ» ÀÌ¿ëÇÏ¿© HPV(Human Papilloma Virus) ¹é½ÅÀ» °³¹ßÇÏ°í ÀÖÀ¸¸ç, ¹Ì±¹ ÇÕÀÛ¹ýÀÎÀÎ EUPOP Life Sciences´Â EcML¢âÀ» ÀÌ¿ëÇÏ¿© Äڷγª19(COVID-19) ¹é½Å, È£Èí±â¼¼Æ÷À¶ÇÕ ¹ÙÀÌ·¯½º(RSV:Respiratory Syncytial Virus)¹é½Å, ´ë»óÆ÷Áø(HZV:Herpes Zoster Virus)¹é½Å, ¾ËÃ÷ÇÏÀ̸Ó(Alzheimer¡¯s Disease) ¹é½ÅÀ» °³¹ßÇÏ°í ÀÖ½À´Ï´Ù.
Á¦Ç°¸í EcML¢â
Á¦Ç°±¸ºÐ ¿¬±¸¿ë ¹× »ó¾÷¿ë
¿ëµµ ¸é¿ªÁõ°­¿ë
ÆǸÅÁ¤º¸ Licensing °¡´É
GMP Grade
°¡°Ý : 240,000/mg(5mg ÀÌ»ó ±¸¸Å °¡´É)
ƯÇã 1) ¸ð³ëÆ÷½ºÆ÷¸± ÁöÁú A¸¦ ±¸¼ºÀûÀ¸·Î »ý»êÇÏ´Â ¼¼±Õ, ¹× À̸¦ ÀÌ¿ëÇÑ ¸ð³ëÆ÷½ºÆ÷¸± ÁöÁú A »ý»ê ¹æ¹ý(ƯÇã¹øÈ£: 10-2019331)
2) Çí»ç ¾Æ½ÇÈ­µÈ ¸ð³ëÆ÷½ºÆ÷¸± ÁöÁú A¸¦ »ý»êÇÏ´Â ¼¼±Õ, ¹× À̸¦ ÀÌ¿ëÇÑ Çí»ç ¾Æ½ÇÈ­µÈ ¸ð³ëÆ÷½ºÆ÷¸± ÁöÁú A »ý»ê ¹æ¹ý(ƯÇã¹øÈ£: 10-1761348)
³í¹® 1) Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960009/)
2) E.coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350214/)
Monophosphoryl lipid A from recombinant E.coli

Á¦Ç°¼ººÐ

Source
Escherichia coli

Á¦Ç°Á¤º¸

Æ÷Àå´ÜÀ§ ÀúÀå¹æ¹ý À¯È¿±â°£ ¼øµµ
1.0mg, 5.0mg/vial
°í°´¸ÂÃãÇü Á¦ÀÛ°¡´É
2 ~ 8¡É Á¦Á¶ÀϷκÎÅÍ 12°³¿ù 95% ÀÌ»ó